Archive: Company News

MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA

— FDA grants RPDD for the treatment of Duchenne muscular dystrophy (DMD)

— MetrioPharm may be eligible for a priority review voucher with a market value in excess of USD 100 million

— MetrioPharm has recently raised CHF 18 million for the development of MP1032 in DMD in a Series D round and is targeting a second closing

MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.

Read more…

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

— Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumors

— Trial overview presented at ESMO Congress 2023 (Madrid, Spain)

— Dose levels 1 and 2 successfully completed

ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced an update on the ongoing Phase 1a/b trial of its lead program IOS-1002 in Australia. The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Read more…

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

– Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors  

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2023ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, today announced a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its lead compound IOS-1002 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in an ongoing Phase 1a/b clinical trial for the treatment of patients with advanced solid tumors.

Read more…

Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial

– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression

– First data readout expected in Q1/ 2024 with study completion planned for September 2024

Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced the successful completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the safety, tolerability, and clinical outcomes of MyopiaX® in pediatric participants with myopia. Read more…

1 5 6 7 161